Irsamla

Vortioxetine, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adults, helping to improve mood and functional outcomes.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Vortioxetine acts on serotonergic pathways to treat depressive disorders. - Major depressive disorder: reduces depressive symptoms and improves functional outcomes in adult patients. - Depressive episodes in major depressive disorder: alleviates mood disturbances and associated cognitive deficits. - Treatment‑resistant major depressive disorder (adjunctive use): may be considered when other antidepressants have not achieved sufficient response.

Irsamla may cause a range of adverse reactions.

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Serotonin syndrome (potentially life‑threatening) - Severe allergic reaction (anaphylaxis)

Before initiating therapy, consider the following precautions. - Assess psychiatric history: monitor for worsening depression or suicidal ideation. - Evaluate hepatic function: adjust use in patients with severe liver impairment. - Avoid concomitant MAO inhibitors: ensure an appropriate washout period. - Caution in cardiovascular disease: monitor blood pressure and heart rate. - Pregnancy and lactation: discuss potential risks with the prescriber. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Vortioxetine can interact with several medication classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol, linezolid, methylene blue): increased serotonin toxicity.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise vortioxetine plasma levels. - CYP2D6 inducers (e.g., rifampin): may reduce drug exposure. - Anticoagulants (e.g., warfarin): monitor INR for potential bleeding risk.